Amy K. O’Sullivan

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Suzanne Lentzsch, Amy K. O’Sullivan, Ryan Kennedy et al. · Blood · 2012 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Cost Estimation of Cardiovascular Disease Events in the US

Amy K. O’Sullivan, Jaime Rubin, Joshua Nyambose et al. · PharmacoEconomics · 2011 · 86 citations

Pharmacy, Economics, Pharmacoeconomics +14

Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids

Amy K. O’Sullivan, David R. Thompson, Paula Chu et al. · International Journal of Technology Assessment in Health Care · 2009 · 74 citations · Full text

Pharmacy, Pharmacoeconomics, Surgery +17

Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System

Matthew Sussman, Amy K. O’Sullivan, Ankit Shah et al. · Journal of Managed Care & Specialty Pharmacy · 2019 · 65 citations · Full text

Pharmacy, Pharmacoeconomics, Psychiatry +17

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands

Wiro B. Stam, Amy K. O’Sullivan, Bart Rijnders et al. · European Journal Of Haematology · 2008 · 49 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15